相关实验视频
Updated: May 29, 2026
09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
治疗抑制miR-208a可以改善心脏功能和心力衰竭期间的存活率
Rusty L Montgomery1, Thomas G Hullinger, Hillary M Semus
1miRagen Therapeutics, Inc, Boulder, CO 80301, USA.
Circulation
|September 9, 2011
概括
使用反感性寡核酸的微RNA-208a (miR-208a) 的治疗抑制改善了高血压大鼠的心脏功能和重塑,这表明了心脏病的新治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 在RNA治疗方面,RNA疗法.
背景情况:
- 由于心脏缩导致的透支功能障碍是一个重要的临床问题,治疗方法有限.
- 微RNAs调节基因表达,影响各种生物过程.
- 以前的研究表明,心脏特异性的miR-208a删除可以防止不良的心脏重塑.
研究的目的:
- 为了研究miR-208a在透缩功能障碍和心脏病中的作用.
- 在心力衰竭的临床前模型中评估抑制miR-208a的治疗潜力.
主要方法:
- 系统性输送反感性寡核酸 (antimiR-208a) 来静止心脏中的miR-208a.
- 利用了高血压引起的心力衰竭的达尔高血压大鼠.
- 评估心脏功能,病理重塑,基因表达和生存.
主要成果:
- 根据剂量的不同,皮下使用antimiR-208a可以预防病态肌肉蛋白切换和心脏重塑.
- 在高血压大鼠中,治疗抑制miR-208a改善了心脏功能,整体健康和生存.
- 转录分析显示,抗miR-208a对心脏基因表达和循环miRNA水平有显著影响.
结论:
- 基于寡核酸的疗法可以有效调节心脏microRNAs.
- miR-208a是管理心脏功能和心脏病重塑的强有力的治疗点.
- 这些发现支持开发基于RNA的新型治疗心血管疾病的方法.
更多相关视频
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
08:03Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...